biotech - genomik - therapeutik - genchips :ALLES IN EINEM FONDS ! - 500 Beiträge pro Seite

[biotechholder]

Gibts das? DAS GESAMTE SPEKTRUM DES BUSINESS OF THE NEW
MILLENIUM IN EINEM FONDS??

-
z.b:
Celera...hat jetzt schon Vertraege mit Amgen, Pfizer und Novartis (!) Um auf die Genomik-Daten zugreifen zu koennen zahlen diese Leader bereits jetzt USD 10 Millionen pro Jahr (!)

Mann des Jahres wird Craig Venter, CEO und Gruender von
Celera sein, und da winkt auch noch der N O B E L P R E I S!

--
Millenium Pharma. (MLNM) entwickelt im Moment 10 (zehn!)
verschiedene Medikamente nur allein gegen Fettleibigkeit (jetzt bereit fuer die klinischen Tests.) Dies ist allerdings nur der kleinste Teil der gesamten Produktepalette von MLNM...!!

---
Amgen (AMGN) Groesstes Biotech-Unternehmen der Welt, gehoert als Basisanlage in JEDES dynamische Depot!
Amgen verbucht schon seit Jahren Gewinne!

----
Genzyme (GENZ): HOCH-PROFITABEL, jetzt schon!
KGV von nur 28!! Schwerpunkt sind Therapeutika gegen
Infektionskrankheiten.

-----
und 16 weitere Biotech-Stars, alles diese Aktien sind
im Fond drin!!!

Genentech (DNA:Nasdaq - news - boards) 20.51%
Amgen (AMGN:Nasdaq - news - boards) 13.28
Immunex (IMNX:Nasdaq - news - boards) 13.24
PE Biosystems (PEB:NYSE - news - boards) 8.5
Biogen (BGEN:Nasdaq - news - boards) 6.32
MedImmune (MEDI:Nasdaq - news - boards) 4.55
Chiron (CHIR:Nasdaq - news - boards) 4.43
Celera (CRA:NYSE - news - boards) 4.16
Human Genome Sciences (HGSI:Nasdaq - news - boards) 3.98
Millennium Pharmaceuticals (MLNM:Nasdaq - news - boards) 3.33
Sepracor (SEPR:Nasdaq - news - boards) 3.07
Affymetrix (AFFX:Nasdaq - news - boards) 2.61
IDEC Pharmaceuticals (IDPH:Nasdaq - news - boards) 2.58
Genzyme (GENZ:Nasdaq - news - boards) 1.87
Alkermes (ALKS:Nasdaq - news - boards) 1.71
QLT PhotoTherapeutics (QLTI:Nasdaq - news - boards) 1.57
Gilead Sciences (GILD:Nasdaq - news - boards) 1.41
ICOS (ICOS:Nasdaq - news - boards) 1.02
BioChem Pharma (BCHE:Nasdaq - news - boards) 1.01
Enzon (ENZN:Nasdaq - news - boards) 0.85

*As of March 1. Source: Merrill Lynch.


BIOTECHHOLDER von Merrill Lynch ! ! !

Boerse: AMEX

Symbol: BBH

Last Paid: USD 160.--

JETZT KAUFEN!!!!
SOLANGE ES NOCH HAT!!!!

best wishes:

h.r.fox
[e-mail]

[biotechholder]

aus dem Motley Fool Research fuer Biotech:
------------------------------------------

...Let`s see if we can reduce biotech investing to a reasonably simple formula.

Divide and Conquer

First of all, there`s a wide variety of biotechnology companies out there. Some of them are already making rules in the industry and are raking in huge profits from products already on the market.
Others have promising research pipelines and are close to breaking through with a new blockbuster drug that will propel them to profitability.
Still others have promising technology but are still in the early stages of development.
To simplify matters, I suggest that investors divide biotech companies into three groups:
1.) a top tier, which represents the established, large-cap biotech companies;

2.) a second tier, which includes companies that are close to being profitable;

3.) and a third tier, which includes everybody else.

The top tier consists of companies that already have one or more successful products on the market and enjoy minimum annual revenues of $500 million. Here are some of the companies in this tier:

Amgen (Nasdaq: AMGN) ,
Biogen (Nasdaq: BGEN) ,
Chiron (Nasdaq: CHIR) ,
Genentech (NYSE: DNA) ,
Genzyme (Nasdaq: GENZ) ,
Immunex (Nasdaq: IMNX) ,
Medimmune (Nasdaq: MEDI) ,
Biochem Pharma (Nasdaq: BCHE) ,
and PE Biosystems (NYSE: PEB) .

My advice to investors who want some biotech exposure but don`t want to go back to school to get a biology degree? Start with this top tier. The companies on this list are all either profitable or will likely be profitable within the next year or two. In addition, the revenues that these companies are pulling in allow them to invest more money in research & development programs.
While still risky, these companies will likely hold up better than others in the event of a disappointment in their research pipeline. They will probably also be more resilient in a nasty market sell off than second- and third-tier companies would. Finally, these companies lend themselves to traditional financial analysis much more readily than the other biotechs.

Now let`s move on to the second group. There are many fine companies in this group that have either drugs on the market with growing sales or drugs that are potential big sellers in late-stage clinical trials. Also included here are the early movers in the much-publicized race to provide genetic information and gene-based drug discovery services.
Let`s call this group tier two. Some of the companies in this tier will go on to become huge winners, while others will never quite break through. All of them involve significant risk.

Some of the companies in tier two are:

Gilead Sciences (Nasdaq: GILD) ,
IDEC Pharmaceuticals (Nasdaq: IDPH) ,
ICOS (Nasdaq: ICOS) ,
Celera Genomics (NYSE: CRA) ,
Millennium Pharmaceuticals (Nasdaq: MLNM) ,
Incyte Pharmaceuticals (Nasdaq: INCY) ,
Human Genome Sciences (Nasdaq: HGSI) ,
and Affymetrix (Nasdaq: AFFX) .

Beyond the second tier, there are all those companies still looking to get their first drug to market or who are struggling to gain acceptance for their technology platforms. We`ll call these the third tier companies.
The companies in this group pose even higher risk than the companies in the second tier. Of course, the opportunity for huge percentage returns is also there, since many of these companies haven`t been discovered by individual investors and are still off the radar screen of most institutions.

Professional biotech investors and those with specialized knowledge have an edge with such companies, but an industrious Fool can still find a gold nugget in these waters.

If you find yourself captivated by a biotech company but don`t know how to proceed, use the checklist below to help you in your analysis. It will help you in assigning your prospective investment to one of our three categories.

Der Biotechholder Fonds von Merrill Lynch hat alle diese Aktien und
mehr!!

Last Price: 158 USD

Stock Echxchange: AMEX

Symbol: BBH

-----------------------------------------------------------------
Fazit: Es gibt keine sicherere Alternative um in diesem riskanten
Umfeld auch groebere Zwischenabstuerze zu ueberleben!
-----------------------------------------------------------------

mit erfolgreichen greetings

h.r.fox
www.feel.ch
[e-mail]

[biotechholder]

JETZT ODER NIE:

abgesehen vom Biotechholder (BBH)empfehle ich schwerstens:

CELL GENESYS
(CEGE)

Die Firma hat im Februar einen Anteil von ihrer
Abgenix (ABGX) -beteiligung verkauft! FUER FAST 200 MILLIONEN USD!!

Die Kassen sind also gefuellt!
(Im Oktober 1999 wollte die Firma uebrigens mit Genzyme (GENZ)
fusionieren, das eruebrigte sich dann allerdings, dank des rasanten
Anstiegs von Abgenix!)

Ferner arbeitet die Firma zusammen mit:

- Mitotix Inc.
- EntreMed Inc.
- Pharmacia & Upjohn
- Rigel Pharmaceutis

...und hat bereits ueber 200 Patente, und weitere in Vorbereitung!

Ich habe ein Oktober 35 Put auf Cell Genesys geschrieben (also Short-position)
dafuer habe ich USD 12.75 kassiert (also 100 x 12.75 = USD 1`275.--)

Falls die Aktie Mitte Oktober immer noch unter USD 35.-- notiert
muesste ich 100 Aktien zum Preis von USD 35.-- uebernehmen, da ich
aber die 1`275.-- jetzt ja schon habe, wuerde mich das nur noch
USD 2`225.-- kosten. (Fuer 100 Aktien dieser Super-firma ein Spott-Preis)

Und das Gesamt-Risiko ist ebenfalls auf diese USD 2`225.-- beschraenkt, da die Aktie ja nicht tiefer als null sinken kann!!!

also, sofort zur tat schreiten:

www.cellgenesys.com

Aloha,
H.R.Fox
[e-mail]